Physician profile
Nancy Graves
NPI 1013138361
$12,598.23
in general payments reported to CMS, 2019-2025
36 companies · $3,420 in 2025
The $3,420 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $515 · 2021: $1,727 · 2022: $1,659 · 2023: $2,546 · 2024: $1,158 · 2025: $3,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,069 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,069.10 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,381.75 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,844.19 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,596.84 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $707.40 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $626.14 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $581.67 | 2020-2025 | Trintellix |
| Lundbeck LLC | $450.10 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $447.23 | 2021-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $421.21 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $409.28 | 2019-2022 | |
| Harmony Biosciences LLC | $397.68 | 2022-2025 | Wakix |
| Axsome Therapeutics, INC. | $378.22 | 2022-2025 | Sunosi, Auvelity |
| Ironshore Pharmaceuticals INC. | $310.53 | 2019-2023 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $274.46 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Tris Pharma INC | $223.58 | 2019-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.